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ABSTRACT   
 
The cannabinoid receptor CB2 plays a significant role in the regulation of immune function 
whereas neuronal expression remains a subject of contention.  Multiple studies have 
described CB2 in retina and a recent study showed that CB2 deletion altered retinal visual 
processing.  We revisited CB2 expression using immunohistochemistry and a recently 
developed CB2-eGFP reporter mouse.  We examined the consequence of acute vs. 
prolonged CB2 deactivation on the electroretinogram (ERG) responses.  We also examined 
lipidomics in CB2 knockout mice and potential changes in microglia using Scholl analysis.  
Consistent with a published report, in CB2 receptor knockout mice see an increased ERG 
scotopic a-wave, as well as stronger responses in dark adapted cone-driven ON bipolar 
cells and, to a lesser extent cone-driven ON bipolar cells early in light adaptation.  
Significantly, however, acute block with CB2 antagonist, AM630, did not mimic the results 
observed in the CB2 knockout mice whereas chronic (7 days) block did.  
Immunohistochemical studies show no CB2 in retina under non-pathological conditions, 
even with published antibodies.  Retinal CB2–eGFP reporter signal is minimal under 
baseline conditions but upregulated by intraocular injection of either LPS or carrageenan.  
CB2 knockout mice see modest declines in a broad spectrum of cannabinoid-related lipids.  
The numbers and morphology of microglia were unaltered. In summary minimal CB2 
expression is seen in healthy retina.  CB2 appears to be upregulated under pathological 
conditions.  Previously reported functional consequences of CB2 deletion are an adaptive 
response to prolonged blockade of these receptors.  CB2 therefore impacts retinal signaling 
but perhaps in an indirect, potentially extra-ocular fashion.  
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Of the two canonical cannabinoid receptors (CB1 and CB2), CB1 receptors are expressed in 
the synaptic layers of the retina in species ranging from salamander to primate (Straiker et 
al., 1999a; Straiker et al., 1999b) where they have been shown to alter neuronal function in 
both photoreceptors and bipolar cells (Straiker et al., 1999a; Straiker and Sullivan, 2003).  
The question of whether CB2 receptors are also expressed in retina has swung pendulum-
like from initial studies that mostly failed to detect CB2 ((Buckley et al., 1998; Porcella et al., 
1998; Porcella et al., 2000) vs. (Lu et al., 2000)) to a consensus for functional CB2 in retina 
based on a growing number of publications.  This includes immunohistochemical evidence 
(Bouskila et al., 2013; Cecyre et al., 2014; Cecyre et al., 2013; Lopez et al., 2011; 
Maccarone et al., 2016), and studies showing altered electroretinogram responses involving 
CB2 receptor function in mouse (Cecyre et al., 2013; Imamura et al., 2018).  There is 
evidence that CB2, long associated with immune function (Atwood et al., 2012), regulates 
ocular inflammation (reviewed in (Toguri et al., 2016)) and there is evidence for retinal 
neuroprotection as a consequence of CB2 activation (Imamura et al., 2018) or antagonism 
(Maccarone et al., 2016).  With this growing body of evidence the presence of functional 
CB2 receptors in the retina seems certain, particularly since two studies used knockout 
controls (Cecyre et al., 2014; Cecyre et al., 2013).  However a definitive localization for CB2 
remains elusive since the expression studies of Lopez et al. and Cecyre et al., Bouskila et 
al., Maccarone et al., and Lu et al. each shows different localization for CB2. The difference 
between these studies may be due to species-related differences (rat, mouse and vervet 
monkey) but this is surprising given the general conservation of retinal structure across 
species.  Even the studies carried out in mice, Cecyre et al., Maccarone et al., and Lu et al. 
are inconsistent with one another.  It should be noted that the cannabinoid field has 
struggled with a consistent lack of specificity among the numerous CB2 antibodies that have 
been developed and tested (reviewed in (Atwood and Mackie, 2010; Atwood et al., 2012)).  
Still, the subsequent finding using electroretinograms (ERGs) that CB2 (but not CB1) 
deletion alters retinal signaling (Cecyre et al., 2013) reinforced the idea that there is a CB2-
based cannabinoid signaling system that directly modulates the retinal output.  These 
findings had implications for the general question of functional CB2 in neurons - itself a 
subject of debate – since the evidence for functional CB2 in neurons has rested largely on 
the work of two groups, one working in the hippocampus and ventral tegmental area (Zhang 
et al., 2016) and one working in the retina (Bouskila et al., 2016; Cecyre et al., 2014; Cecyre 
et al., 2013).   
 
We have revisited the question of CB2 presence and function in the retina in somewhat 
greater detail, using a combination of ERGs, lipidomics, immunohistochemistry and a novel 






C57BL/6J (WT) and CB2R KO mice (C57BL/6J, background strain) were used for all 
experiments except the lipidomics analyses that used CB2 KO mice back-crossed onto a 
BALB/c background, compared to BALB/c strain-mates.  Experimental procedures 
performed in Canada complied with Canadian Council on Animal Care (http://www.ccac.ca).  
Experiments were approved by respective animal care committees at Dalhousie University 
and Indiana University. 
 
Immunohistochemistry 
For CB2 antibody testing the following procedure was followed.  Adult mice (C57/BL6 strain, 
> 5 weeks, of either sex, from breeding colony) were housed under a 12/12 hour day/night 
cycle, then sacrificed.  Eyes were removed, and the anterior eye section cut away and the 
lens extracted, leaving an eyecup.  For immunocytochemistry, the posterior eyecup was 
fixed in 4% paraformaldehyde for an hour followed by a 30% sucrose immersion for 24-72 
hours at 4°C.  Tissue was then frozen in OCT compound and sectioned (15-25 μm) using a 
Leica CM1850 cryostat.  Tissue sections were mounted onto Fisher Superfrost-plus slides, 
washed, blocked with SEABLOCK blocking buffer (Thermo Fisher) for 30 minutes, treated 
with a detergent (Triton X-100, 0.3% or saponin, 0.1%), followed by primary antibodies 
overnight at 4 °C.  Anti-CB2 polyclonal antibodies were obtained as listed in Table 1.  To 
visualize microglia, retinas were stained with primary antibodies Anti-Iba-1 Polyclonal 
Antibody (Cat: 019-19741; 1:200, Wako Chemicals USA).  eGFP signal was detected using 
a pre-labeled anti-GFP antibody (Alexa647-labeled, Cat#: A-31852 ThermoFisher).  
Secondary antibodies (Alexa488, Alexa 594 or Alexa647, 1:500, Invitrogen) were 
subsequently applied at room temperature for 1.5 hours.  Microscopy was carried out at 
Indiana University and images were acquired with a Leica TCS SP5 confocal microscope 
(Leica Microsystems, Wetzlar, Germany) using Leica LAS AF software and a 40x or 63x oil 
objective. Images were processed using FIJI (https://imagej.net/Fiji/, provided in the public 
domain by the National Institutes of Health, Bethesda, MD, USA) and Photoshop (Adobe, 
Inc., San Jose, CA, USA). Images were modified only in terms of brightness and contrast. 
 
Table 1.  Commercial CB2 antibodies tested 
Antibody Host Vendor Cat # Lot number 
CB2 Rabbit Abcam ab3561 GR145565-3, GR209773-1 
CB2 Rabbit Cayman Chemical Company 101550 0437 135-1 
CB2 Rabbit Affinity Bio Reagents PA1-744 423-107 
CB2R Rabbit Alomone Labs ACR-002 AN-01 
CB2 (M-15) Goat Santa Cruz Biotechnology SC-10076 E2314 
 
 
Scholl analysis of Iba1-stained microglia was done using the FIJI plugin Simple Neurite 
Tracer (Longair et al., 2011) to map out the morphology of the microglial cell in three 
dimensional space and calculate the number of process crossings at 5 micron intervals.  
 
Generation of CB2R-GFP Reporter Mice 
Generation of CB2R-GFP reporter mice has been described (Lopez et al., 2018). Briefly an 
eGFP reporter gene preceded by an IRES sequence in the 3’ UTR of the CNR2, (CB2) 
mouse gene was inserted into the embryonic stem cells of C57BL/6j mice resulting in the 
expression of the reporter gene under the control of the endogenous mouse CB2R promoter 
and transcription from the same bicistronic mRNA as the CB2R protein.  The mouse model 
(CB2R eGFP/f/f) was generated by homologous recombination in embryonic stem cells, in 




Mice were first injected with an analgesic (0.05 mg/kg buprenorphine, IP), followed by 
general isoflurane anesthesia.  While the animal was anesthetized, intravitreal injection of 
either saline, or LPS in saline, was given through the pars plana, under a dissecting 
stereomicroscope using a Hamilton syringe fitted to a 30G needle. Control animals received 
2 μL of sterile saline, while experimental animals are injected with 250 ng lipopolysaccharide 
(LPS; 125 ng μL-1; E. coli 026:B6 L8274; Sigma-Aldrich) in 2 μL of saline. The animal was 
allowed to revive then monitored for three hours, after which the animal was euthanized and 
the eyes collected for analysis of GFP expression.  The procedure for carrageenan was the 




The function of CB2 receptors in the retina was investigated by recording 
electroretinographic responses (ERGs) under light conditions designed to isolate rod and 
cone driven responses under dark (scotopic), and light adapted (photopic) conditions. We 
tested CB2R KO vs. wild type animals, and additionally tested the consequence of 
administration of CB2 receptor antagonist AM630 (2.5mg/kg, IP).   AM630 experiments 
consisted either of a single treatment or a chronic treatment (7 days, twice a day, every 12h 
intraperitoneal injection).  
Electroretinographic protocols have been described in detail elsewhere (Smith et al., 2013). 
Briefly mice between 13 and 17 weeks of age were dark-adapted for 8-12h overnight and 
anesthetized under dim red light by intraperitoneal injection of Avertin (2,2,2 
Tribromoethanol) dissolved in amylene hydrate (tertiary amyl alcohol, 275 mg/kg).  Pupils 
were dilated with 1% tropicamide (mydriadicyl); a topical analgesic was applied to reduce 
eye movement and irritation.  Body temperature was maintained at 37°C with a heated pad 
and monitored rectally.  Mice were sacrificed by anesthetic overdose followed by cervical 
dislocation.  The interval between stimuli varied between 15 s for paired flash experiments to 
1 s for light-adapted stimuli.  5–20 responses were averaged depending on stimulus 
strength.  Paired flash stimuli to isolate dark-adapted cone responses used a 500 ms inter-
flash interval.  ERG waveform analysis was performed according to the standard method 
(McCulloch et al., 2015).  The a-wave amplitude was measured from baseline to the trough 
of the a-wave and the b-wave amplitude was measured from the trough of the a-wave to the 
positive peak of the b-wave. Statistical analysis was performed by using unpaired t-test and 
two-way ANOVA followed by Bonferroni post hoc test.  Experimental values were presented 
as means ± SEM; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001.   
 
Lipid Extraction and LC/MS/MS Analysis and Quantification  
 
Enucleated eyes were flash frozen in liquid nitrogen and frozen at -80°C until used for lipid 
analysis.  Levels of ~30 cannabinoid-related lipids as well as arachidonic acid and several 
prostaglandin-family metabolites were measured by liquid chromatography/mass 
spectrometry from whole eyes as previously described (Bradshaw et al., 2009).  Briefly, 
eyes from six animals for each condition (two eyes pooled as one sample) were 
homogenized, centrifuged at 19,000 x g 24°C for 20 min and supernatant was collected.  
Compounds were isolated using a partial purification of the 25% organic solution.  C18 solid-
phase extraction columns (Agilent Technologies, Santa Clara, CA) were used with an 
elution of 100% methanol.  
Samples were placed in an autosampler and held at 24°C (Agilent 1100 series autosampler, 
Palo Alto, CA) for LC/MS/MS analysis.  10-20 µL of eluents were injected for each sample 
which was rapidly separated using a C18 Zorbax reversed-phase analytical column (Agilent 
Technologies, Santa Clara, CA) to scan for individual compounds. Gradient elution (200 
µL/min) then was accomplished under pressure (Shimadzu 10AdVP pumps, Columbia, MD).  
The electrospray ionization was done using an API3000 triple quadrupole mass 
spectrometer (Applied Biosystems/DSM Sciex, Foster City, CA).  A multiple reaction 
monitoring (MRM) setting on the LC/MS/MS was used to analyze levels of each compound. 
Synthetic standards were used to generate optimized MRM methods and standard curves 
for analysis.  
 
Individual animals in each of the treatment groups were coded and experiments were 
analyzed in a blinded fashion.  All data are presented as mean ± SEM and were analyzed in 
GraphPad Prism v. 5 (GraphPad Software Inc., La Jolla, CA, USA).  LC/MS/MS lipidomics 
data was analyzed by one-way ANOVA with a Fisher’s Least Significant Difference post-hoc 
test.  All groups were normally distributed according to the Kolmogorov-Smirnov test.  P < 





Revisiting CB2 immunohistochemistry in retina 
Cecyre et al. (Cecyre et al., 2014; Cecyre et al., 2013) tested multiple antibodies against 
CB2 to characterize protein expression in retina.  These studies used knockout controls and 
identified one of the antibodies as delivering staining that was absent in knockout tissue, i.e. 
a validated CB2 antibody.  Pronounced expression was seen in both synaptic layers, in the 
ganglion cell layer and also in photoreceptor inner segments.  All staining was absent in 
CB2 knockout retinas.  This antibody, from Cayman Chemical (See Table 1 for details) was 
obtained by us and tested in murine retina, also using knockout controls.   
 
As reported by Cecyre et al. (Cecyre et al., 2014), the staining was most prominent in the 
inner plexiform layer (Fig. 1, IPL).  The staining we observe for this antibody is both similar 
to that reported by Cecyre et al., and to the staining in knockout controls and therefore 
inconsistent with valid CB2 expression.  We also tested a variety of other commercially 
available CB2 antibodies (Table 1) but none offered staining that was absent in CB2 KO 
tissue (Figure S4).   As noted in the introduction the specificity of CB2 antibodies has been a 
persistent issue since the receptors were first identified.  This has prompted the 
development of alternative strategies to identify where these receptors are expressed 
including CB2-eGFP reporter mice.  
 
 
Figure 1.  Cayman CB2 antibody yields similar staining in WT and CB2 knockout 
tissue.  A) CB2 antibody staining in retina using Cayman Chemical antibody previously 
validated in knockout controls by Cecyre et al. (2013, 2014).  B) Staining for CB2 in 





Minimal signal in baseline CB2-eGFP reporter mice is upregulated after intraocular 
injection of LPS or carrageenan. 
 
The CB2-eGFP mouse model was developed to offer an alternative assay for CB2 
expression.  Designed to produce eGFP untethered to CB2 but under a CB2 promoter 
(Lopez et al., 2018), this CB2-eGFP reporter mouse identifies which cells express CB2 but 
not where within a cell CB2 is expressed.  As shown in Figure 2A only minimal eGFP 
staining is seen in murine retina.  We occasionally observed dim microglia-like staining in 
the INL but the staining is sparse, representing a small subset of microglia.  Because of the 
immune-CB2 link we tested whether an inflammatory insult might upregulate CB2 
expression.   We tested the consequence of intraocular injection of LPS and in a separate 
experiment carrageenan (Toguri et al., 2015).  As shown in Figures 2B,D each treatment 
resulted in a substantially enhanced eGFP signal particularly in the ganglion cell layer but 
also to a lesser extent in the proximal inner nuclear layer.  The staining appears to 
correspond to golgi or endoplasmic reticulum, presumably as a result of rapidly upregulated 
expression in response to inflammatory insult.      
 
 
Figure 2.  CB2 is upregulated from low baseline levels by LPS/carrageenan in murine 
retina.  A) GFP staining is minimal in CB2-eGFP reporter mouse.  A1) corresponding DIC 
image. B-C) Intraocular LPS injection induces an eGFP signal in CB2-eGFP reporter (B) but 
not in WT (C) mice. B&C were taken at same settings in single microscopy session to allow 







ERG responses are altered 
in CB2 KO mice relative to 
wild type controls 
Consistent with previous 
findings (Cecyre et al., 2013), 
we see an alteration of the 
ERG response profile in CB2 
knockout mice vs. strain 
controls.  The scotopic a-wave 
is significantly increased (*, 
p<0.05 to ***, p<0.001) at 
higher stimulus strengths in 
CB2 knockouts while the b-
wave is not (Fig. 3B).  In dark-
adapted conditions the cone-
driven response is also 
significantly increased (Fig. 
3C).  The cone-driven b-wave 
remained significantly 
elevated during light 
adaptation and when fully light 
adapted, the b-wave is 
increased above -0.2 
log cd m s−2  (***, p<0.001). 
 
During light adaptation we 
found that the b-wave 
responses were also modestly 
enhanced in CB2 knockouts 
Figure 3. ERG responses are altered in CB2 KO 
mice relative to wild type controls A-B) Amplitudes 
of scotopic ERG a-wave (A) and b-wave (B) plotted as 
a function of flash luminance.  C) Amplitudes of 
scotopic ERG dark-adapted cone-driven response 
after rod saturation.  D) The amplitudes of photopic 
ERG b-wave are plotted as a function of flash 
luminance.  E) The amplitudes of photopic ERG b-
wave are plotted as a function of time.  *, p<0.05, **, 
p<0.01, ***, p<0.001, 2-way ANOVA with Bonferroni 
post hoc test 
 
relative to wild type mice (Fig. 3D).  We also examined whether this changed over time as 
the animals were light-
adapted, finding that the 
difference was maintained 
for 15 minutes, though it 
was no longer statistically 
significant at 20 mins.  
We additionally examined 
whether CB2 deletion 
altered the latencies of 
ERG responses.  We found 
that CB2 KO mice did not 
have altered latencies (Fig. 
S1). The sole exception 
was a shorter latency in 
CB2 KOs at the highest 
flash intensity Fig. S1C).  
 
Acute pharmacological 
blockade of CB2 
receptors does not mimic 
the ERG alterations seen 
in CB2 KO mice  
If CB2 participates in an 
active retinal signaling 
system, and CB2 deletion 
alters retinal signaling, then 
one would predict that an 
antagonist of CB2 would 
similarly alter signaling.  
We therefore tested the 
Figure 4.  Acute treatment with CB2 antagonist does 
not mimic alteration of ERG seen in CB2 KO mice.  
Animals were treated with a CB2 antagonist AM630 (2.5 
mg/kg, IP).  A-B) Amplitudes of scotopic ERG a-wave (A) 
and b-wave (B) plotted as a function of flash luminance.  
C) Amplitudes of scotopic ERG dark adapted cone-driven 
response after rod saturation.  D) The amplitudes of 
photopic ERG b-wave are plotted as a function of flash 
luminance.  E) The amplitudes of photopic ERG b-wave 
are plotted as a function of time.  *, p<0.05, **, p<0.01, ***, 
p<0.001, 2-way ANOVA with Bonferroni post hoc test 
 
ERG responses in wild type mice treated with the CB2 antagonist, AM630 (2.5mg/kg, IP).  
Surprisingly, we found that this treatment was without any effect on either scotopic or 
photopic responses (Fig. 3) even though similar concentrations were found to block CB2 
activation in rats and mice (Lehmann et al., 2012; Toguri et al., 2014).   We also examined 
whether acute AM630 treatment altered the latencies of ERG responses, finding that there 






Figure 5.  Prolonged treatment with CB2 antagonist 
recapitulates alteration of ERG seen in CB2 KO mice.  
Animals were treated with CB2 antagonist twice daily for 
seven days. A-B) Amplitudes of scotopic ERG a-wave (A) 
and b-wave (B) plotted as a function of flash luminance.  
C) Amplitudes of scotopic ERG dark adapted cone-driven 
response after rod saturation.  D) The amplitudes of 
photopic ERG b-wave are plotted as a function of flash 
luminance.  E) The amplitudes of photopic ERG b-wave 
are plotted as a function of time.  *, p<0.05, **, p<0.01, ***, 








Chronic (1 week) pharmacological blockade of CB2 receptors in adults does mimic 
ERG alterations seen in CB2 KO mice. Genetic deletion of a receptor can have 
unexpected consequences, either developmental or adaptive in nature.  The lack of effect of 
acute treatment with AM630 suggests that the altered retinal signaling seen in CB2 
knockouts is due to such an adaptive or developmental effect.  CB2 is intimately involved in 
immune function and the deletion of CB2 has been shown to enhance inflammation (Mecha 
et al., 2016).  In order to dissect whether the altered signaling in CB2 knockouts is 
developmental/adaptive in nature we tested whether a prolonged weeklong blockade of CB2 
receptors in adults was sufficient to mimic these changes.  We found that repeated AM630 
treatments twice-daily for one week recapitulated all of the consequences of CB2 genetic 
deletion, with enhancement of the scotopic a-wave (Fig. 5A), dark-adapted cone-driven 
response (Fig. 5C) and photopic b-wave (Fig. 5D,E).  The treatment additionally enhanced 
the scotopic b-wave, which had been unaffected by CB2 deletion (Fig. 5B).  We also 
examined whether chronic AM630 treatment altered the latencies of ERG responses.  In 
contrast to a single treatment which had no effect on latencies, chronic treatment altered 
latencies in several instances.  Scotopic responses were unaltered (Fig. S3A-B), but as with 
CB2 KOs, the photopic response was faster at the highest flash intensity (Fig S3C).  This 
difference persisted over time (Fig. S3E).  The dark-adapted cone-driven response also saw 
a slightly faster latency.   
    
 
 
CB2 KO mice have lower levels of 
many cannabinoid-related lipids 
We examined the cannabinoid-related 
lipid profile in eyes of CB2 KO vs. wild-
type mice (n=6 biological replicates per 
condition).   Levels of most lipids were 
lower (Table 2), particularly the 
acylethanolamines that declined as a 
class, though modestly.  Interestingly 
linoleic acid and arachidonic acid both 
declined as did prostaglandins PGE2 and 
PGF2α. Levels of the endocannabinoid 2-
AG were unaltered but 2-OG, a ligand at 















Table 2: Levels of many cannabinoid-
related lipids are lower in CB2 KO mouse 
eyes.  LC-MS-MS measurements of 
cannabinoid-related lipids.  Red indicates 
statistically significant changes.  Pink 
indicates trend (1.0>p>0.05).  Arrows 
indicate fold change. 1 arrow: 1-1.49; 2 
arrows: 1.5-1.99; 3 arrows: 2-2.99  
 
Figure 6.  Microglial numbers are not altered in CB2 KO relative to wild type (WT) 
retina. A) Sample retina flatmount stained for Iba1.  B-C) Sample image from CB2 knockout 
and wild type retinas showing microglial cells stained with Iba1.  D) Summary shows that 
microglial numbers are not altered in CB2 knockouts relative to wild type retina (n=4 retinas 
per condition).   
 
 
Microglial cell numbers and morphology are unaltered in CB2 KO mice. 
CB2 receptors are chiefly found in components of the immune system including microglia 
and activation of CB2 generally suppresses immune cells (reviewed in (Turcotte et al., 
2016)).  The absence of CB2 might be expected to enhance immune responses, perhaps 
including microglia that are seen in retina.  To explore this further we examined the numbers 
of retinal microglia, finding that the numbers of microglia are unaltered in CB2 knockout 
retina (Fig. 6D, n=4 retinae per condition).   We also examined the morphology of microglia 
using Scholl analysis.  Activated microglia are proposed to exhibit a differential, more 
compact morphology (reviewed in (Yu et al., 2015)).   As shown in Figure 7, we did not 
detect a change in the number of crossings (Fig. 7, WT (n=9 cells); CB2 KO (n=11 cells); 








Our chief finding is that, consistent with published 
findings (Cecyre et al., 2013), cannabinoid CB2 
receptor blockade impacts retinal function but that 
this occurs only with prolonged, not acute, block of 
CB2.  A single treatment with CB2 antagonist 
AM630 is without effect while twice-daily treatment 
over the course of a week recapitulates the altered 
responses seen in CB2 knockout mice.  In contrast 
to published findings, using a combination of 
immunohistochemistry and a newly developed 
CB2-eGFP reporter mouse, we see only minimal 
CB2 expression in retina under baseline conditions 
but CB2 appears to be upregulated in retina in 
response to inflammatory challenge.  It remains 
unclear how prolonged systemic blockade of CB2 
results in altered retinal signaling.  The mechanism 
may involve altered cannabinoid metabolism since 
levels of many endogenous cannabinoids decline 
in CB2 knockouts.  The changes do not appear to 
be due to altered number or activation of microglia 
as measured by Scholl analysis.  
 
The question of what role if any the cannabinoid 
signaling system might play in the retina was first 
raised by the discovery of robust and highly 
conserved CB1 receptor expression in the retinae 
of various species ranging from salamander to 
primate (Straiker et al., 1999a), including humans 
Figure 7.  Microglial 
morphology is unaltered CB2 
KO relative to wild type (WT) 
retina. A) Summary Scholl 
analysis of microglia in WT vs. 
CB2 knockout retina.  B-C) 
Sample images from CB2 
knockout (B, n=11) and wild type 
(C, n=9) retinas showing 
microglial cells stained with Iba1, 
with processes mapped and 
analyzed using Simple Neurite 
Tracer.   
(Straiker et al., 1999b).  This was followed by a series of in vitro studies indicating that these 
receptors might alter synaptic transmission at both synaptic layers (Straiker et al., 1999a; 
Straiker and Sullivan, 2003) as they do elsewhere in the CNS (reviewed in (Kano et al., 
2009)).  As discussed in the introduction the situation for CB2 was less clear partly because 
of contradictory studies of mRNA expression but also because the cannabinoid field has 
struggled to develop convincing tools to determine the expression of CB2, particularly in 
neurons.  An ERG study showing altered light responses in CB2 knockouts but not CB1 
knockouts (Cecyre et al., 2013) was therefore both surprising and intriguing.    
It is broadly accepted that CB2 plays a role in immune modulation, with expression seen in 
several cell types of the immune system including monocytes, macrophages and microglia 
CB2 activation is generally seen to suppress immune responses (reviewed in (Buckley, 
2008)).  Evidence for CNS expression of CB2 was largely limited to microglial expression 
under inflammatory conditions (e.g. (Cabral and Marciano-Cabral, 2005)) until a series of 
studies reporting functional CB2, chiefly in the ventral tegmental area and hippocampus 
(Zhang et al., 2015; Zhang et al., 2016).  The above-mentioned reports of CB2-mediated 
alterations of neuronal function in retina were therefore a significant step in favor of a 
neuronal role for CB2.   
 
The staining pattern we observed with the Cayman antibody is broadly similar to that 
reported by Cecyre et al. (Cecyre et al., 2014; Cecyre et al., 2013) in mouse, but is still 
present in CB2 knockout tissue.  Cecyre et al. stated that they had tested several lots of the 
CB2 antibody and that staining by some antibody lots was not credible.  The lot number that 
they published (0424681-1) was different from the lot number tested by us.  So in principle, 
the lack of unique CB2 signal may be a function of lot-specificity.  It is actually somewhat 
surprising that the Cayman antibody should have yielded specific staining in mouse given 
that it was developed against amino acids 20-33 of the human CB2 receptor.  In contrast to 
CB1, CB2 receptors are not especially well conserved across species (~82% identity for 
human vs. mouse).  The sequence in question differs at 4 of 14 residues (i.e. 29%) relative 
to the mouse CB2 receptor, making it an unlikely choice for conservation of cross-species 
reactivity.  Indeed, the staining pattern reported using the same antibody in vervet monkey 
retina, for which knockouts are unavailable, was very different (Bouskila et al., 2013) even 
though retinal circuitry is by and large well-maintained across species.  The CB1 staining 
pattern is broadly conserved in species as disparate as primate and salamander (Straiker et 
al., 1999a; Straiker and Sullivan, 2003).  It should be noted that the CB2 staining differs 
even across the two studies by Cecyre et al using the same preparation and antibody (and 
lot), with one showing prominent staining in the outer limiting membrane and ganglion cells 
(Cecyre et al., 2013), the other not (Cecyre et al., 2014).  The CB2 staining is also wholly 
different from that reported by Lopez et al. (2011) in rat using an antibody (aa 326-342 of rat 
CB2, provided by Ken Mackie) and from that reported by Maccarone et al (2016) using an 
Abcam antibody.  Like Cecyre et al., we have tested numerous other CB2 antibodies in 
retina but have not found them to yield credible staining (e.g. Fig. S4).  Our negative IHC 
results taken alone do not rule out retinal CB2 expression, but it is worth noting in this 
context that three of four studies that examined CB2 mRNA in retina ((Buckley et al., 1998; 
Porcella et al., 1998; Porcella et al., 2000) vs. (Lu et al., 2000)) did not detect CB2.  For this 
reason we also incorporated newly developed CB2-eGFP reporter mice into our study.  
These mice produce eGFP in cells that natively express CB2 and so serve as a useful tool 
to determine which cells and tissues express CB2 though they do not offer insight into 
subcellular localization of those receptors since eGFP is not tethered to CB2.  Our finding 
that baseline expression of eGFP in these mice is minimal is consistent with the hypothesis 
that under baseline conditions CB2 is expressed only modestly if at all in retina.  However 
we did see an upregulation of eGFP after inflammatory insult with either LPS or 
carrageenan, thereby validating the CB2-eGFP model for study of ocular CB2 expression.  
The greatest upregulation of CB2 however was seen in the ganglion cell layer.  Changes in 
ganglion cell signaling would not be expected to alter the a and b waves of the ERG.   
 
We have clarified ERG findings showing that prolonged, but not acute, block of CB2 alters 
retinal signaling.  But we have also offered several lines of evidence that CB2 is minimally 
expressed under normal conditions in the retina.  So how does this alteration of retinal 
signaling occur if there are few if any CB2 receptors?  Given the role of CB2 in immune 
responses, alteration of some component of the ocular or systemic immune response is a 
possibility.  To explore this we examined whether profile of endocannabinoid-related lipids 
was altered in the CB2 knockout mice.  We did see declines in many endocannabinoids 
including the acylethanolamines that include anandamide (AEA) a likely cannabinoid 
receptor ligand.  Since the acylethanolamines declined as a class and these lipids are 
produced and metabolized enzymatically this suggests that CB2 deletion alters the 
cannabinoid-related enzymatic profile.  This could occur via upregulation of the enzyme 
FAAH which metabolizes this class of lipids (Cravatt et al., 2001) or perhaps downregulation 
of NAPE-PLD, an enzyme linked to production of these lipids (Leishman et al., 2016).  
Several N-arachidonoyl glycines also saw declines, but of the N-arachidonoyl glycerols, 
which include the endocannabinoid 2-arachidonoylglycerol (2-AG) (Sugiura et al., 1995), 
only 2-oleoylglycerol (2-OG) changed.  2-OG has been proposed to serve as an 
endogenous ligand for the GPR119 receptor (Syed et al., 2012).  Because there are also 
changes in the levels of some free fatty acids, this may in turn impact other lipids including 
prostaglandins, some of which have been shown to be dependent on metabolism of 
endocannabinoid precursors (Nomura et al., 2011).   
 
We separately examined whether microglia changed in numbers or morphology in CB2 
knockout mice.  We did see occasional CB2 positive staining in microglial-like cells in the 
CB2 reporter mice this was dim and very sparse.  It is however consistent with evidence for 
CB2 expression in microglia (Stella, 2010).  We quantified both the numbers of microglia 
and also a measure of their activation state using Scholl analysis, but saw no changes in 
either variable.  The changed signaling may not therefore depend on altered microglial 
function.   
 
Since our experiments raise questions about CB2 expression it should also be noted that 
cannabinoid pharmacology has also proven complicated.   For instance we have shown that 
the nominally selective and commonly used CB2 receptor agonist JWH015 is efficacious 
and reasonably potent at CB1 receptors (Murataeva et al., 2012) and that the antagonist 
AM630 also antagonizes CB1 receptors at concentrations commonly used by researchers 
(Lehmann et al., 2012; Toguri et al., 2014).  
 
In summary, while we have confirmed that CB2 deletion has consequences for retinal 
function, we find through a combination of functional and protein expression studies that this 
is unlikely to be due to acute activation of a retinal CB2 signaling system.  A prolonged (i.e. 
week-long) systemic blockade of CB2 receptors alters several aspects of retinal signaling 
but it remains to be determined how this occurs since there are few if any CB2 receptors in 
the retina under normal conditions.  An indirect effect of systemic CB2 blockade on retinal 
signaling is itself an interesting finding and highlights the potential for indirect consequences 
of systemic drug treatments even for the relatively isolated retina.  
 











































Figure S1.  Latencies in CB2 KO vs. WT.   A-B) Latencies for scotopic a-
waves (A) and b-waves (B) in control vs. CB2 KO mice.  C) Latencies for 
photopic reponses.  D) Amplitudes of scotopic ERG dark adapted cone-driven 
response after rod saturation.  E) Latencies for b-wave plotted vs. adaptation 
time.  *, p<0.05, **, p<0.01, ***, p<0.001, 2-way ANOVA with Bonferroni post 
hoc test. 
Figure S2.  Latencies are unaffected by acute AM630 treatment.   A-B) 
Latencies for scotopic a-waves (A) and b-waves (B) in control vs. AM630-
treated animals.  C) Latencies for photopic reponses.  D) Amplitudes of 
scotopic ERG dark adapted cone-driven response after rod saturation.  E) 
Latencies for b-wave plotted vs. adaptation time.  *, p<0.05, **, p<0.01, ***, 






Figure S3.  Latencies for chronic AM630 treatment.   A-B) Latencies for scotopic 
a-waves (A) and b-waves (B) in control vs. AM630-treated animals.  C) Latencies for 
photopic reponses.  D) Amplitudes of scotopic ERG dark adapted cone-driven 
response after rod saturation.  E) Latencies for b-wave plotted vs. adaptation time.  *, 





Figure S4.  Testing retinal staining for CB2 antibodies with knockout controls.   In 
addition to the Cayman antibody (Fig. 1) we tested several other commercially available 
CB2 antibodies including ones from A) Affinity Bioscience, B) Abcam, C) Alomone Labs, and 
D)Santa Cruz Biotechnology.  See Table 1 for antibody details.  Antibodies were tested in 
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